全文获取类型
收费全文 | 6257篇 |
免费 | 278篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 115篇 |
妇产科学 | 68篇 |
基础医学 | 532篇 |
口腔科学 | 133篇 |
临床医学 | 444篇 |
内科学 | 1894篇 |
皮肤病学 | 94篇 |
神经病学 | 357篇 |
特种医学 | 351篇 |
外科学 | 1216篇 |
综合类 | 22篇 |
预防医学 | 112篇 |
眼科学 | 60篇 |
药学 | 337篇 |
中国医学 | 18篇 |
肿瘤学 | 802篇 |
出版年
2023年 | 30篇 |
2022年 | 35篇 |
2021年 | 138篇 |
2020年 | 86篇 |
2019年 | 109篇 |
2018年 | 152篇 |
2017年 | 119篇 |
2016年 | 134篇 |
2015年 | 168篇 |
2014年 | 206篇 |
2013年 | 245篇 |
2012年 | 445篇 |
2011年 | 427篇 |
2010年 | 271篇 |
2009年 | 182篇 |
2008年 | 357篇 |
2007年 | 416篇 |
2006年 | 379篇 |
2005年 | 408篇 |
2004年 | 416篇 |
2003年 | 425篇 |
2002年 | 370篇 |
2001年 | 83篇 |
2000年 | 71篇 |
1999年 | 78篇 |
1998年 | 82篇 |
1997年 | 79篇 |
1996年 | 51篇 |
1995年 | 53篇 |
1994年 | 51篇 |
1993年 | 44篇 |
1992年 | 33篇 |
1991年 | 40篇 |
1990年 | 42篇 |
1989年 | 40篇 |
1988年 | 34篇 |
1987年 | 36篇 |
1986年 | 24篇 |
1985年 | 34篇 |
1984年 | 17篇 |
1983年 | 20篇 |
1982年 | 13篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 14篇 |
1977年 | 14篇 |
1974年 | 10篇 |
1970年 | 10篇 |
1969年 | 12篇 |
1968年 | 11篇 |
排序方式: 共有6591条查询结果,搜索用时 15 毫秒
1.
Masaki Shiota Eiji Kashiwagi Tomohiko Murakami Ario Takeuchi Kenjiro Imada Junichi Inokuchi Katsunori Tatsugami Masatoshi Eto 《Urologic oncology》2019,37(3):180.e19-180.e24
Purpose
Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC.Patients and methods
The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined.Results
Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively.Conclusions
The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC. 相似文献2.
Atsushi Hata Takahiro Nakajima Keisuke Matsusaka Masaki Fukuyo Junichi Morimoto Takayoshi Yamamoto Yuichi Sakairi Bahityar Rahmutulla Satoshi Ota Hironobu Wada Hidemi Suzuki Hisahiro Matsubara Ichiro Yoshino Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(2):388-399
3.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
4.
5.
6.
Keigo Yamashita Takehisa Abe Yoshihiro Hayata Tomoaki Hirose Shun Hiraga Ryohei Fukuba Junichi Takemura Rei Tonomura Kazuki Yamamoto Shinya Yokoyama Shigeki Taniguchi 《Journal of thoracic disease》2020,12(11):6609
BackgroundCopeptin, the C-terminal portion of the arginine vasopressin precursor, is a novel candidate biomarker. This study investigated the prognostic value of copeptin levels following cardiac surgery for the occurrence of postoperative acute kidney injury.MethodsWe studied 23 patients who underwent cardiac surgery between January 2018 and December 2019. The primary endpoint was postoperative acute kidney injury onset. Copeptin levels were measured before, right after, and daily for 7 days. The patients were divided into two groups according to the copeptin levels: low (values <43.7 pmol/L) and high (values ≥43.7 pmol/L). Correlations between copeptin levels and variables, such as central venous pressure, were assessed by bivariate analysis.ResultsThe high copeptin group exhibited significantly higher levels of arginine vasopressin and cortisol following surgery, compared to those of the low copeptin group. The copeptin concentration following surgery was correlated to central venous pressure (P=0.03) and norepinephrine administered dose (P=0.008). Also, the copeptin levels right after surgery robustly predicted the onset of postoperative acute kidney injury (area under the receiver operating characteristic curve of 0.83, P=0.004).ConclusionsElevated copeptin levels in patients following cardiac surgery predicted postoperative acute kidney injury development. Therefore, the copeptin concentration after surgery could represent a promising clinical biomarker of the postoperative cardiac outcome. 相似文献
7.
8.
9.